How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

250 results for

Seasonal Oral Contraceptive Cycle

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Seasonal Oral Contraceptive Cycle

Seasonal Oral Contraceptive Cycle Seasonal Oral Contraceptive Cycle Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Seasonal Oral (...) Contraceptive Cycle Seasonal Oral Contraceptive Cycle Aka: Seasonal Oral Contraceptive Cycle , Extended-Cycle Oral Contraceptive , Seasonale , Lybrel , LoSeasonique , Quartette II. Indications Heavy Women wanting to reduce to 4 times per year III. Techique: Seasonal, 84 day regimen Continue active pills (no pills) until: Breakthrough bleeding or 84 days pass When active phase completed Hormone free: 5-7 days IV. Preparations Any monophasic may be used Simply do not take pills Much less expensive

2018 FP Notebook

2. Seasonal Oral Contraceptive Cycle

Seasonal Oral Contraceptive Cycle Seasonal Oral Contraceptive Cycle Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Seasonal Oral (...) Contraceptive Cycle Seasonal Oral Contraceptive Cycle Aka: Seasonal Oral Contraceptive Cycle , Extended-Cycle Oral Contraceptive , Seasonale , Lybrel , LoSeasonique , Quartette II. Indications Heavy Women wanting to reduce to 4 times per year III. Techique: Seasonal, 84 day regimen Continue active pills (no pills) until: Breakthrough bleeding or 84 days pass When active phase completed Hormone free: 5-7 days IV. Preparations Any monophasic may be used Simply do not take pills Much less expensive

2015 FP Notebook

3. Oral Contraceptive-Related Uterine Bleeding Management

at beginning of next cycle VIII. References Dickey (1998) Managing Contraceptive Pill Patients Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Oral Contraceptive-Related Uterine Bleeding Management." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary (...) Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse

2018 FP Notebook

4. Oral Contraceptive Side Effect Management

Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Aka: Oral Contraceptive Side Effect Management II. Management: Nausea Take pill at bedtime, or at a meal Use Low pill (e.g. ) III. Management: Fluid Retention Change to OCP with the following characteristics Low (or low dose) Examples IV. Management: Appetite too active or weight gain Change to OCP with the following characteristics Low (or low dose) Low Examples V. Management: Hypertension Discontinue Consider

2018 FP Notebook

5. Oral Contraceptive

Effects (10% new ) abnormalities (lowers HDL-2) Adverse effects not associated with Oral Contraceptives Weight gain is not significant Hordinsky (2000) Eighth World Congress Int Gyn Endo VIII. Preparations: Combined Contraceptive Formulations Monophasic Triphasic Triphasic s (20-35 ug) IX. Preparations: Cycle Types Standard: 21 days hormonal, 7 days hormone free Extended: 24 day regimen, 4 days hormone free Seasonal: 84 day regimen, 5-7 days hormone free See X. Efficacy High failure rate with P450 (...) 100,000 per year without aura is not a contraindication to OCP in age <35 and otherwise healthy Do not use if abuse or over age 35 years Limit dose to 20 mg or less Monthly: , Seasonal: , Lo- References Mechanisms related effect and HDL effect Increased risk with higher dose Increased risk with higher age, and exposure of arterial events ( or ) No OCP: 3 arterial events per 10,000 women under age 50 years On OCP: 4-5 arterial events per 10,000 women under age 50 years Oral Contraceptive alone: 3

2018 FP Notebook

6. Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral transdermal contraceptive (TDC) therapy and contraceptive vaginal ring (CVR) therapy are also tested. Millions of women use COC therapy for birth control purposes or regulation of menstrual cycles. TDC and CVR therapies are relatively new FDA-approved contraceptive alternatives to COC. The purpose of the proposed project is to address the potential mechanism(s) by which oral (...) -term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis. Other Name: Apri (Reclipsen) Experimental: Transdermal Contraceptive (TDC) Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly

2015 Clinical Trials

7. A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

the flu season, which is allowed 7 days before or after dosing Note 2: Allowed medications include: oral contraceptives; H1 antihistamines; topical/ intranasal corticosteroids; nonsteroidal anti-inflammatory drugs [NSAIDS]; licensed influenza vaccine during the flu season, 7 days before or after dosing. 14) Use of any non-prescription medication, herbal preparation, or nutritional supplement within 15 days before dosing or planned use during the study unless approved by the study clinician Note (...) , salpingectomy, oophorectomy or tubal ligation/occlusion; vasectomy), or abstinence. Use of methods with higher failure rate (such as progestin injectables, combined oral hormonal contraceptives, condoms, and diaphragms) will not be acceptable when used alone, but they could be considered if used in combination with another method (e.g., a female using combined oral contraceptives if her male partner is sterile, or if she and her non-sterile male partner use a double-barrier method), after consultation

2018 Clinical Trials

8. Oral Contraceptive Side Effect Management

Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Aka: Oral Contraceptive Side Effect Management II. Management: Nausea Take pill at bedtime, or at a meal Use Low pill (e.g. ) III. Management: Fluid Retention Change to OCP with the following characteristics Low (or low dose) Examples IV. Management: Appetite too active or weight gain Change to OCP with the following characteristics Low (or low dose) Low Examples V. Management: Hypertension Discontinue Consider

2015 FP Notebook

9. Oral Contraceptive-Related Uterine Bleeding Management

at beginning of next cycle VIII. References Dickey (1998) Managing Contraceptive Pill Patients Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Oral Contraceptive-Related Uterine Bleeding Management." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary (...) Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse

2015 FP Notebook

10. Oral Contraceptive

Effects (10% new ) abnormalities (lowers HDL-2) Adverse effects not associated with Oral Contraceptives Weight gain is not significant Hordinsky (2000) Eighth World Congress Int Gyn Endo VIII. Preparations: Combined Contraceptive Formulations Monophasic Triphasic Triphasic s (20-35 ug) IX. Preparations: Cycle Types Standard: 21 days hormonal, 7 days hormone free Extended: 24 day regimen, 4 days hormone free Seasonal: 84 day regimen, 5-7 days hormone free See X. Efficacy High failure rate with P450 (...) 100,000 per year without aura is not a contraindication to OCP in age <35 and otherwise healthy Do not use if abuse or over age 35 years Limit dose to 20 mg or less Monthly: , Seasonal: , Lo- References Mechanisms related effect and HDL effect Increased risk with higher dose Increased risk with higher age, and exposure of arterial events ( or ) No OCP: 3 arterial events per 10,000 women under age 50 years On OCP: 4-5 arterial events per 10,000 women under age 50 years Oral Contraceptive alone: 3

2015 FP Notebook

11. Assessing the Impact of Contraceptives on Bone Health Using 41Ca

contraceptive (COC) therapy on bone turnover are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral contraceptive therapy, such as vaginal contraceptive (CVR) therapy is also tested. Millions of women use COC therapy for birth control purposes or regulation of menstrual cycles. CVR therapy is a relatively new FDA-approved contraceptive alternative to COC. The purpose of the proposed project is to investigate whether oral ethinyl (...) by (Responsible Party): Mary Jane DeSouza, Penn State University Study Details Study Description Go to Brief Summary: This preclinical randomized crossover study will examine the effects of oral versus non-oral contraceptive therapy on bone turnover in young exercising women. In an effort to expose the route-dependent effects of oral versus non-oral contraceptive therapy on bone turnover, the investigators will examine 1) the effects of ethinyl estradiol on bone calcium balance using the 41Ca technology and 2

2015 Clinical Trials

12. Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias

Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02882282 Recruitment Status : Recruiting First Posted : August 29, 2016 Last Update Posted

2016 Clinical Trials

13. Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

using hormonal contraceptives must also be using an additional approved method of contraception (as described previously) starting at Cycle 1 Day 1, and continuing throughout the entire study period and for 2 months after the last dose of study drug. Postmenopausal women must have been amenorrheic for at least 12 consecutive months; otherwise a pregnancy test is required. Male patients must agree to use contraceptive methods (eg, abstinence, condom + spermicide or a double-barrier method [eg, condom (...) Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2015 Clinical Trials

14. A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

a negative serum and urine B-hCG test result at Screening and Baseline. Females of child-bearing potential must agree to use a medically acceptable method of contraception (e.g., abstinence; a highly effective method such as an intrauterine device [IUD], condom + spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral contraceptive; or have a vasectomized partner) throughout the entire study period and for 30 days after study drug discontinuation. The only subjects who (...) cycle prior to starting study drug(s) and throughout the entire study and for 30 days after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Provide written informed consent Are willing and able to comply with all aspects of the protocol Exclusion Criteria Subjects who had a clinically significant illness that required medical treatment within 8 weeks or a clinically significant

2014 Clinical Trials

16. Prepregnancy counseling

postoperatively. During this period, pregnancy is less desirable because of potential effects on fetal growth. Contraceptive counseling during the postoperative period is important because the risk of oral contraceptive failure in patients who have bariatric surgery with a malabsorptive component is increased. Counseling regarding the bene?ts of nonoral contraceptive or LARC methods is recommended. x – Mood disorders Impaired maternal infant bonding, risk of maternal self-harm, or neglect. Antidepressants (...) testing can be alteredin women who are pregnant or using oral contraceptive pills, so leukocyte testing must be used in these patients.* * Carrier screening for genetic conditions. Committee Opinion No. 691. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e41–55. y Hemoglobinopathies in pregnancy. Practice Bulletin No. 78. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;109:229–37. ASRM and ACOG. Prepregnancy counseling. Fertil Steril 2019. VOL

2019 Society for Assisted Reproductive Technology

17. Male Sexual Dysfunction

in the general population. Urology, 2001. 57: 970. 6. Kulmala, R.V., et al. Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol, 1995. 29: 93. 7. Furtado, P.S., et al. The prevalence of priapism in children and adolescents with sickle cell disease in Brazil. Int J Hematol, 2012. 95: 648. 8. Adeyoju, A.B., et al. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int, 2002. 90: 898. 9. Emond, A.M., et al. Priapism (...) for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology, 2015. 3: 909. 159. Rosen, R.C. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am, 2001. 28: 269. 160. Lue, T.F. Erectile dysfunction. N Engl J Med, 2000. 342: 1802. 161. Yuan, J., et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol, 2013. 63: 902. 162. Goldstein, I., et al

2019 European Association of Urology

18. Ciclosporin (Verkazia) - Conjunctivitis, Keratitis

by an inflammation of the conjunctivitis with corneal involvement and tissue remodelling including papillae formation. It was first described by Arlt in 1846 who reported 3 cases of perilimbal swelling in young patients. The association with springtime (vernal) reflects the seasonal increase in signs and symptoms of the condition, particularly the high prevalence in hot, arid environments. Affected individuals have disease flares frequently during spring months, but can have signs and symptoms year round (...) -derived cytokines, interleukins IL-4, IL-5 and IL-13, other cytokines, chemokines, growth factors and enzymes are over- expressed in the conjunctiva of VKC patients (Leonardi et al., 2009). Furthermore, structural cells, such as epithelial cells and fibroblasts, are involved both in the inflammatory process and in the tissue remodelling phase. 2.1.4. Clinical presentation, diagnosis and stage/prognosis VKC is differentiated from other ocular allergic conditions, such as seasonal or perennial allergic

2018 European Medicines Agency - EPARs

19. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

randomised to placebo in period A were assigned to receive adalimumab 40 mg every week in period B. Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods. In period A, patients received placebo or adalimumab at an initial dose of 160 mg at week 0 and 80 mg at week 2 and 40 mg every week starting at week 4 to week 11. 19.3 % of patients had continued baseline oral antibiotic therapy during the study. After 12 weeks of therapy, patients who had received adalimumab in period A were re (...) despite treatment with corticosteroids (oral prednisone at a dose of 10 to 60 mg / day). All patients received a 2-week standardised dose of prednisone 60 mg / day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by week 15. Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral prednisone 10 to 35 mg / day) at baseline to control their disease. Patients subsequently underwent a mandatory taper

2018 European Medicines Agency - EPARs

20. Risk factors for breast cancer: A review of the evidence 2018

polymorphisms 47 4.3.11 STK11 gene mutation 50 4.3.12 TP53 gene mutation 52 4.4 Breast pathology 54 4.4.1 Previous benign breast disease 54 4.4.2 LCIS 55 4.4.3 DCIS 59 4.4.4 Previous primary invasive breast cancer 60 4.5 Endogenous hormones 63 4.5.1 Age at menarche 63 4.5.2 Parity 64 4.5.3 Age at first birth 65 4.5.4 Breastfeeding 67 4.5.5 Age at menopause 68 4.5.6 Circulating hormones—steroids 69 4.5.7 PCOS 72 4.6 Exogenous hormones 74 4.6.1 Hormonal contraception—combined 74 4.6.2 Hormonal contraception (...) Hormonal contraception—combined and risk of breast cancer 301 Table D.29 Hormonal contraception—progestogen only and risk of breast cancer 305 Table D.30 Menopausal hormone therapy—combined and risk of breast cancer 309 Table D.31 Menopausal hormone therapy—oestrogen only and risk of breast cancer 315 Table D.32 Hormonal infertility treatment and risk of breast cancer 319 Table D.33 DES in utero and risk of breast cancer 324 Table D.34 DES maternal exposure and risk of breast cancer 326 Table D.35

2018 Cancer Australia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>